Olaparib induced aplastic anemia in a patient with castrate resistant prostate cancer: A case report

Area of Science:

• Oncology
• Pharmacology
• Genetics

Background:

• Olaparib is a poly (ADP-ribose) polymerase inhibitor (PARPi) approved for metastatic castration-resistant prostate cancer (CRPC).
• PARPi therapy targets cancer cells with BRCA1/BRCA2 mutations or homologous recombination deficiency by inhibiting DNA repair.
• While myelodysplastic syndrome and acute leukemia have been reported with PARPi use, aplastic anemia is not a commonly associated adverse event.

Observation:

• A 75-year-old male patient with BRCA2-positive metastatic CRPC received olaparib treatment.
• The patient subsequently developed aplastic anemia.

Findings:

• This case report documents the first instance of aplastic anemia following olaparib therapy in a patient with prostate cancer.
• The patient's BRCA2 mutation status and the mechanism of PARPi action are key considerations.

Implications:

• This finding expands the known spectrum of potential adverse events associated with olaparib and PARP inhibitors.
• Further investigation into the risk of aplastic anemia in patients receiving PARPi therapy is warranted.
• Clinical monitoring for hematological toxicities should be vigilant in patients undergoing PARPi treatment.